Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Abcellera Biologics Inc
8QQAbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. Address: 2215 Yukon Street, Vancouver, BC, Canada, V5Y 0A1
Analytics
Preço Alvo de Wall Street
12.29 USDRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave 8QQ
Análise de Dividendos 8QQ
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos 8QQ
Avaliação de ações 8QQ
Relatório 8QQ
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |